About
Diasome Pharmaceuticals develops liver-targeted insulin and metabolic therapies that deliver drugs directly to the portal-hepatic region to improve glycemic control and reduce hypoglycemia risk in diabetes patients.
Explore Diasome Pharmaceuticals's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.